Ishihara, H., Yamaguchi, S., Nakao, I., & Sakatani, T. (2018). Ipragliflozin Add-on Therapy to a GLP-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes (AGATE): A 52-Week Open-Label Study. Diabetes Ther.
Chicago ZitierstilIshihara, Hisamitsu, Susumu Yamaguchi, Ikko Nakao, und Taishi Sakatani. "Ipragliflozin Add-on Therapy to a GLP-1 Receptor Agonist in Japanese Patients With Type 2 Diabetes (AGATE): A 52-Week Open-Label Study." Diabetes Ther 2018.
MLA ZitierstilIshihara, Hisamitsu, Susumu Yamaguchi, Ikko Nakao, und Taishi Sakatani. "Ipragliflozin Add-on Therapy to a GLP-1 Receptor Agonist in Japanese Patients With Type 2 Diabetes (AGATE): A 52-Week Open-Label Study." Diabetes Ther 2018.
Achtung: Diese Zitate sind unter Umständen nicht zu 100% korrekt.